[{"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-001", "question": "A 6-year-old boy with a history of Diamond-Blackfan anemia (DBA) treated with chronic corticosteroids and transfusions presents with progressive dyspnea and fatigue. Echocardiography reveals a restrictive cardiomyopathy with severe biventricular diastolic dysfunction and moderate pulmonary hypertension. Genetic testing confirms a pathogenic variant in RPS19. Which of the following is the most appropriate next step in management?", "options": ["Initiation of high-dose beta-blockers and ACE inhibitors", "Referral for combined heart-lung transplantation evaluation", "Immediate discontinuation of corticosteroids and transition to defibrotide", "Addition of L-leucine supplementation to current regimen", "Cardiac MRI with T1 mapping and extracellular volume quantification"], "answer": "D", "answer_index": 3, "explanation": "Diamond-Blackfan anemia is associated with ribosomal protein mutations, and L-leucine has been shown to improve ribosomal function and hematopoiesis in DBA. In patients with DBA-associated cardiomyopathy, addressing the underlying ribosomal dysfunction with leucine supplementation may improve cardiac function, whereas conventional heart failure therapies are less effective for this specific pathophysiology. Beta-blockers/ACE inhibitors would be insufficient, transplantation is premature without addressing the underlying metabolic defect, defibrotide is for hepatic veno-occlusive disease, and advanced imaging would not change management.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (no answer defensible)\\nVerdict on keyed answer: Misleading and not defensible as the single best next step\\nKey stem clues: 6-year-old with Diamond-Blackfan anemia on chronic steroids/transfusions; now has restrictive cardiomyopathy with severe biventricular diastolic dysfunction and moderate pulmonary hypertension. The question asks for the most appropriate next step in management of this advanced cardiac disease.\\nMain logical/medical issues: The keyed answer (D, L‑leucine) is not established therapy for DBA-associated cardiomyopathy; evidence for leucine in DBA is limited and focused on hematologic response, not reversal of restrictive cardiomyopathy or pulmonary hypertension. In a child with severe diastolic dysfunction, the immediate appropriate step would be guideline-directed heart failure/cardiomyopathy management and further cardiac evaluation (e.g., MRI, consideration of advanced therapies, or transplant evaluation), not an experimental hematologic adjunct. Option A is incomplete/nonspecific but more in line with standard care than D; option E (cardiac MRI with T1/ECV) is also plausibly an appropriate next diagnostic step. Thus no option is clearly best per accepted standards, and the explanation incorrectly claims conventional HF therapy is less appropriate.\\nMinimal fix: Rewrite the stem toward hematologic management of DBA (without advanced cardiomyopathy) or change options so one clearly reflects evidence-based cardiomyopathy care; alternatively, rekey to the best-supported cardiac option and adjust explanation accordingly.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (no answer defensible)\nVerdict on keyed answer: Misleading and not defensible as the single best next step\nKey stem clues: 6-year-old with Diamond-Blackfan anemia on chronic steroids/transfusions; now has restrictive cardiomyopathy with severe biventricular diastolic dysfunction and moderate pulmonary hypertension. The question asks for the most appropriate next step in management of this advanced cardiac disease.\nMain logical/medical issues: The keyed answer (D, L‑leucine) is not established therapy for DBA-associated cardiomyopathy; evidence for leucine in DBA is limited and focused on hematologic response, not reversal of restrictive cardiomyopathy or pulmonary hypertension. In a child with severe diastolic dysfunction, the immediate appropriate step would be guideline-directed heart failure/cardiomyopathy management and further cardiac evaluation (e.g., MRI, consideration of advanced therapies, or transplant evaluation), not an experimental hematologic adjunct. Option A is incomplete/nonspecific but more in line with standard care than D; option E (cardiac MRI with T1/ECV) is also plausibly an appropriate next diagnostic step. Thus no option is clearly best per accepted standards, and the explanation incorrectly claims conventional HF therapy is less appropriate.\nMinimal fix: Rewrite the stem toward hematologic management of DBA (without advanced cardiomyopathy) or change options so one clearly reflects evidence-based cardiomyopathy care; alternatively, rekey to the best-supported cardiac option and adjust explanation accordingly.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-002", "question": "A 34-year-old pregnant woman at 32 weeks gestation presents with acute-onset severe hypertension (200/120 mmHg), headache, and visual disturbances. Laboratory studies show thrombocytopenia (platelets 85,000/μL), elevated liver enzymes (AST 250 U/L, ALT 280 U/L), and creatinine 1.8 mg/dL. Magnesium sulfate is initiated. Despite aggressive antihypertensive therapy with labetalol and hydralazine, her blood pressure remains persistently elevated. Which of the following is the most appropriate next pharmacologic intervention?", "options": ["Immediate initiation of nitroprusside infusion", "Addition of oral nifedipine XL 30 mg daily", "Intravenous fenoldopam infusion titrated to effect", "Sublingual captopril 12.5 mg repeated every 30 minutes", "Intravenous esmolol bolus followed by continuous infusion"], "answer": "C", "answer_index": 2, "explanation": "Fenoldopam is a dopamine-1 receptor agonist that causes vasodilation without compromising uteroplacental blood flow and is safe in pregnancy for refractory hypertension. Nitroprusside is contraindicated due to risk of cyanide toxicity to the fetus. Nifedipine XL has slow onset and is inadequate for acute control. ACE inhibitors like captopril are contraindicated in pregnancy due to fetal renal toxicity. Esmolol may cause fetal bradycardia and is less ideal than fenoldopam for pregnancy-associated hypertensive emergencies.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 32‑week pregnancy, severe preeclampsia/eclampsia picture (BP 200/120, headache, visual symptoms, thrombocytopenia, elevated LFTs, elevated creatinine), already on magnesium sulfate and standard IV agents (labetalol, hydralazine) with persistent severe hypertension → refractory hypertensive emergency in pregnancy needing rapid IV control without fetal toxicity.\\n\\nFenoldopam (C) is an IV dopamine‑1 agonist, rapidly titratable, with favorable renal and uteroplacental perfusion effects, and is considered an acceptable option for refractory severe hypertension in pregnancy when first‑line drugs fail. It is therefore the best among the listed choices.\\n\\nWhy others are worse: (A) Nitroprusside is generally avoided in pregnancy due to fetal cyanide/thiocyanate toxicity, reserved only as last‑ditch short‑term use. (B) Nifedipine XL has slow onset and is inappropriate for acute refractory crisis. (D) ACE inhibitor (captopril) is contraindicated in pregnancy (fetal renal dysgenesis, oligohydramnios). (E) Esmolol crosses the placenta and can cause fetal bradycardia and growth restriction; not preferred over fenoldopam given options.\\n\\nMain medical accuracy issue(s): Minor — fenoldopam pregnancy data are limited; it’s a reasonable but not classic first‑line, yet acceptable given the context and distractors.\\n\\nMinimal fix: Clarify “refractory hypertensive emergency despite maximized labetalol and hydralazine” and cite need for “rapidly titratable IV agent safe in pregnancy.”\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 32‑week pregnancy, severe preeclampsia/eclampsia picture (BP 200/120, headache, visual symptoms, thrombocytopenia, elevated LFTs, elevated creatinine), already on magnesium sulfate and standard IV agents (labetalol, hydralazine) with persistent severe hypertension → refractory hypertensive emergency in pregnancy needing rapid IV control without fetal toxicity.\n\nFenoldopam (C) is an IV dopamine‑1 agonist, rapidly titratable, with favorable renal and uteroplacental perfusion effects, and is considered an acceptable option for refractory severe hypertension in pregnancy when first‑line drugs fail. It is therefore the best among the listed choices.\n\nWhy others are worse: (A) Nitroprusside is generally avoided in pregnancy due to fetal cyanide/thiocyanate toxicity, reserved only as last‑ditch short‑term use. (B) Nifedipine XL has slow onset and is inappropriate for acute refractory crisis. (D) ACE inhibitor (captopril) is contraindicated in pregnancy (fetal renal dysgenesis, oligohydramnios). (E) Esmolol crosses the placenta and can cause fetal bradycardia and growth restriction; not preferred over fenoldopam given options.\n\nMain medical accuracy issue(s): Minor — fenoldopam pregnancy data are limited; it’s a reasonable but not classic first‑line, yet acceptable given the context and distractors.\n\nMinimal fix: Clarify “refractory hypertensive emergency despite maximized labetalol and hydralazine” and cite need for “rapidly titratable IV agent safe in pregnancy.”", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-003", "question": "A 58-year-old man with metastatic renal cell carcinoma on nivolumab and ipilimumab combination therapy presents with acute respiratory failure requiring mechanical ventilation. Bronchoalveolar lavage shows lymphocytic predominance without infectious organisms. High-dose methylprednisolone (2 mg/kg/day) was initiated 72 hours ago without improvement. Which of the following is the most appropriate next step in management?", "options": ["Add infliximab 5 mg/kg single dose", "Initiate cyclophosphamide 1 g/m² IV", "Switch to dexamethasone 40 mg daily", "Begin plasma exchange therapy", "Add tocilizumab 8 mg/kg IV"], "answer": "A", "answer_index": 0, "explanation": "For steroid-refractory immune checkpoint inhibitor-related pneumonitis, TNF-alpha inhibition with infliximab is the recommended next-line therapy based on retrospective evidence showing improved outcomes. Cyclophosphamide is used for other immune-related adverse events like myocarditis but not first-line for pneumonitis. Switching corticosteroids is unlikely to help if already on high-dose methylprednisolone. Plasma exchange is not established for this condition. Tocilizumab (IL-6 inhibitor) is used for cytokine release syndrome but not specifically for checkpoint inhibitor pneumonitis.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: Metastatic RCC on nivolumab + ipilimumab (dual checkpoint blockade), acute respiratory failure, BAL with lymphocytic predominance and no organisms → high-grade immune checkpoint inhibitor (ICI) pneumonitis. Already on high-dose methylprednisolone 2 mg/kg/day for 72 hours without improvement → steroid-refractory ICI pneumonitis.\\n\\nMost likely diagnosis/mechanism: Severe, steroid-refractory ICI-related pneumonitis.\\n\\nEvaluation of keyed answer (A): Infliximab is commonly recommended as next-line immunosuppression for steroid-refractory grade 3–4 ICI pneumonitis in major oncology/ASCO/NCCN-type guidance, supported by retrospective data. Thus A is the single best option.\\n\\nOther options: B) Cyclophosphamide has been described for refractory myocarditis or some vasculitic/neurologic irAEs, but is not standard second-line for pneumonitis. C) Switching steroid type without dose escalation or additional agent is unlikely to alter a steroid-refractory course. D) Plasma exchange is not guideline-supported for ICI pneumonitis. E) Tocilizumab is primarily used for CAR-T cytokine release syndrome, with only anecdotal use in ICI toxicities.\\n\\nMain medical/logical issues: Minor—some variability exists in second-line choice (e.g., mycophenolate), but among listed options, infliximab is clearly best.\\n\\nMinimal fix: Specify “severe (grade 3–4) immune checkpoint inhibitor pneumonitis” in the stem to make the teaching point explicit.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: Metastatic RCC on nivolumab + ipilimumab (dual checkpoint blockade), acute respiratory failure, BAL with lymphocytic predominance and no organisms → high-grade immune checkpoint inhibitor (ICI) pneumonitis. Already on high-dose methylprednisolone 2 mg/kg/day for 72 hours without improvement → steroid-refractory ICI pneumonitis.\n\nMost likely diagnosis/mechanism: Severe, steroid-refractory ICI-related pneumonitis.\n\nEvaluation of keyed answer (A): Infliximab is commonly recommended as next-line immunosuppression for steroid-refractory grade 3–4 ICI pneumonitis in major oncology/ASCO/NCCN-type guidance, supported by retrospective data. Thus A is the single best option.\n\nOther options: B) Cyclophosphamide has been described for refractory myocarditis or some vasculitic/neurologic irAEs, but is not standard second-line for pneumonitis. C) Switching steroid type without dose escalation or additional agent is unlikely to alter a steroid-refractory course. D) Plasma exchange is not guideline-supported for ICI pneumonitis. E) Tocilizumab is primarily used for CAR-T cytokine release syndrome, with only anecdotal use in ICI toxicities.\n\nMain medical/logical issues: Minor—some variability exists in second-line choice (e.g., mycophenolate), but among listed options, infliximab is clearly best.\n\nMinimal fix: Specify “severe (grade 3–4) immune checkpoint inhibitor pneumonitis” in the stem to make the teaching point explicit.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-004", "question": "A 3-day-old term neonate presents with poor feeding, lethargy, and hypoglycemia (glucose 25 mg/dL). Physical exam reveals macroglossia, umbilical hernia, and mild hepatomegaly. Newborn screening shows elevated galactose and galactitol. Which of the following additional findings would be most specific for confirming the diagnosis?", "options": ["Elevated serum ammonia level", "Absent reducing substances in urine after lactose challenge", "Normal glycogen content on liver biopsy", "Deficient activity of galactose-1-phosphate uridyltransferase in erythrocytes", "Presence of cataract on ophthalmologic examination"], "answer": "C", "answer_index": 2, "explanation": "The presentation suggests galactosemia, but the key distinguishing feature is that in galactose epimerase deficiency (a rare form), liver biopsy shows normal glycogen content, whereas in classic galactosemia (GALT deficiency), glycogen is depleted. Elevated ammonia suggests urea cycle defect. Absent reducing substances would argue against galactosemia. GALT enzyme deficiency confirms classic galactosemia, not the epimerase variant. Cataracts occur in both forms and are not specific.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (likely also U). Verdict on keyed answer: Miskeyed. The vignette (3-day-old with poor feeding, lethargy, hypoglycemia, macroglossia, umbilical hernia, hepatomegaly, elevated galactose/galactitol) is most consistent with classic galactosemia or another galactose metabolism defect, but macroglossia/umbilical hernia more typically suggest Beckwith-Wiedemann, not galactose epimerase deficiency; the stem never specifies epimerase deficiency. The question asks for the most specific finding “for confirming the diagnosis” after newborn screening already shows elevated galactose/galactitol. The single most specific confirmatory test for galactosemia in standard teaching is deficient GALT activity in erythrocytes (choice D), not “normal glycogen content on liver biopsy” (C), which is indirect, invasive, and only relevant if one has already decided on the rare epimerase variant. Thus the keyed answer C is not the best or most specific confirmatory test; D is. Several other options are clearly incorrect or nonspecific (A, B, E). Minimal fix: either (1) change the key to D and revise explanation accordingly, or (2) explicitly state suspected epimerase deficiency in the stem and reframe the question around distinguishing variants. \",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (likely also U). Verdict on keyed answer: Miskeyed. The vignette (3-day-old with poor feeding, lethargy, hypoglycemia, macroglossia, umbilical hernia, hepatomegaly, elevated galactose/galactitol) is most consistent with classic galactosemia or another galactose metabolism defect, but macroglossia/umbilical hernia more typically suggest Beckwith-Wiedemann, not galactose epimerase deficiency; the stem never specifies epimerase deficiency. The question asks for the most specific finding “for confirming the diagnosis” after newborn screening already shows elevated galactose/galactitol. The single most specific confirmatory test for galactosemia in standard teaching is deficient GALT activity in erythrocytes (choice D), not “normal glycogen content on liver biopsy” (C), which is indirect, invasive, and only relevant if one has already decided on the rare epimerase variant. Thus the keyed answer C is not the best or most specific confirmatory test; D is. Several other options are clearly incorrect or nonspecific (A, B, E). Minimal fix: either (1) change the key to D and revise explanation accordingly, or (2) explicitly state suspected epimerase deficiency in the stem and reframe the question around distinguishing variants. ", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-005", "question": "A 42-year-old woman with systemic lupus erythematosus and antiphospholipid syndrome on warfarin (INR 2.5-3.5) presents with acute right leg pain and swelling. Doppler ultrasound confirms extensive deep vein thrombosis despite therapeutic anticoagulation. Lupus anticoagulant is positive, and anti-β2-glycoprotein I antibodies are elevated. Which of the following management strategies is most appropriate?", "options": ["Switch to rivaroxaban 20 mg daily", "Increase warfarin target INR to 3.5-4.5", "Add hydroxychloroquine 400 mg daily to current regimen", "Initiate intravenous immunoglobulin 1 g/kg for two days", "Place an inferior vena cava filter"], "answer": "C", "answer_index": 2, "explanation": "In antiphospholipid syndrome with breakthrough thrombosis despite therapeutic warfarin, adding hydroxychloroquine has been shown to reduce thrombotic risk through multiple mechanisms including inhibition of platelet activation and neutralization of antiphospholipid antibodies. Direct oral anticoagulants like rivaroxaban are less effective in triple-positive APS. Higher INR targets increase bleeding risk without proven benefit. IVIG is reserved for catastrophic APS. IVC filters do not address the hypercoagulable state and increase long-term DVT risk.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M/K. Verdict on keyed answer: Not uniquely determinable; item appears miskeyed relative to most guidelines. Key stem clues: 42-year-old woman with SLE and antiphospholipid syndrome, triple-positive (lupus anticoagulant, anti–β2-GPI), on warfarin with therapeutic high-intensity INR 2.5–3.5, now with extensive acute DVT (“breakthrough” VTE). The key path is recurrent thrombosis despite therapeutic warfarin in high-risk APS.\\nCurrent EULAR/ASH-type guidance generally supports: (1) verifying adherence/INR, then (2) considering switch to LMWH or addition of low-dose aspirin; also consider IVC filter in extensive/limb-threatening DVT when anticoagulation is failing. Hydroxychloroquine is sometimes used adjunctively in APS, but robust guideline-level evidence for adding HCQ as the primary next step in recurrent VTE on therapeutic warfarin is limited and not standard “most appropriate” management. Meanwhile, an IVC filter (E) is a defensible option in the setting of extensive DVT despite anticoagulation, especially if embolic risk is high. Thus both C and E can be argued; no option reflects recommended LMWH switch. The rationale overstates evidence for HCQ.\\nMinimal fix: Change option set to include “Switch from warfarin to therapeutic low–molecular weight heparin” as the correct key and remove IVC filter, or revise stem to emphasize arterial events/prevention where HCQ is clearly adjunctive.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M/K. Verdict on keyed answer: Not uniquely determinable; item appears miskeyed relative to most guidelines. Key stem clues: 42-year-old woman with SLE and antiphospholipid syndrome, triple-positive (lupus anticoagulant, anti–β2-GPI), on warfarin with therapeutic high-intensity INR 2.5–3.5, now with extensive acute DVT (“breakthrough” VTE). The key path is recurrent thrombosis despite therapeutic warfarin in high-risk APS.\nCurrent EULAR/ASH-type guidance generally supports: (1) verifying adherence/INR, then (2) considering switch to LMWH or addition of low-dose aspirin; also consider IVC filter in extensive/limb-threatening DVT when anticoagulation is failing. Hydroxychloroquine is sometimes used adjunctively in APS, but robust guideline-level evidence for adding HCQ as the primary next step in recurrent VTE on therapeutic warfarin is limited and not standard “most appropriate” management. Meanwhile, an IVC filter (E) is a defensible option in the setting of extensive DVT despite anticoagulation, especially if embolic risk is high. Thus both C and E can be argued; no option reflects recommended LMWH switch. The rationale overstates evidence for HCQ.\nMinimal fix: Change option set to include “Switch from warfarin to therapeutic low–molecular weight heparin” as the correct key and remove IVC filter, or revise stem to emphasize arterial events/prevention where HCQ is clearly adjunctive.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-006", "question": "A 67-year-old man with ischemic cardiomyopathy (LVEF 25%) and cardiac resynchronization therapy defibrillator presents with recurrent appropriate shocks for ventricular tachycardia. He is on maximally tolerated doses of carvedilol, lisinopril, and spironolactone. Amiodarone was started but discontinued due to thyroid toxicity. Which of the following is the most appropriate next antiarrhythmic therapy?", "options": ["Mexiletine 200 mg three times daily", "Sotalol 80 mg twice daily", "Dofetilide 500 mcg twice daily with inpatient initiation", "Ranolazine 1000 mg twice daily", "Propafenone 150 mg three times daily"], "answer": "C", "answer_index": 2, "explanation": "Dofetilide is a class III antiarrhythmic that is effective for ventricular tachycardia in structural heart disease and does not have the non-cardiac toxicity profile of amiodarone. It requires inpatient initiation due to risk of torsades de pointes. Mexiletine has limited efficacy as monotherapy. Sotalol is contraindicated in severe systolic dysfunction. Ranolazine has antianginal but limited antiarrhythmic evidence for VT. Propafenone is contraindicated in structural heart disease due to proarrhythmic risk.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (miskeyed)\\nVerdict on keyed answer: Miskeyed – option C is not the best defensible answer.\\n\\nKey stem clues: 67-year-old man, ischemic cardiomyopathy with LVEF 25% (severe systolic dysfunction/structural heart disease), CRT-D, recurrent appropriate ICD shocks for VT despite optimal GDMT; amiodarone discontinued for thyroid toxicity. The question asks for the most appropriate next antiarrhythmic.\\n\\nIn structural heart disease with low EF and VT, class Ic agents (propafenone) are contraindicated; dofetilide is used for AF/flutter, not for VT suppression. The explanation’s claim that dofetilide is effective for VT is not standard or guideline-supported. Sotalol, a class III with beta-blocking properties, is an accepted option for VT suppression in ICD patients with ischemic cardiomyopathy and EF ~25%, provided careful QT and renal monitoring; many guidelines list it as a reasonable next-line antiarrhythmic when amiodarone cannot be used. Thus B is more defensible than C. Mexiletine monotherapy, ranolazine, and propafenone are clearly inferior/unsafe.\\n\\nMain medical accuracy issue: misrepresentation of dofetilide’s role in VT and overstatement that sotalol is contraindicated purely by low EF.\\n\\nMinimal fix: Change the key and explanation so that sotalol (B) is the correct answer, and rewrite rationale appropriately; or change option C to a clearly guideline-endorsed VT agent (e.g., catheter ablation rather than another drug).\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (miskeyed)\nVerdict on keyed answer: Miskeyed – option C is not the best defensible answer.\n\nKey stem clues: 67-year-old man, ischemic cardiomyopathy with LVEF 25% (severe systolic dysfunction/structural heart disease), CRT-D, recurrent appropriate ICD shocks for VT despite optimal GDMT; amiodarone discontinued for thyroid toxicity. The question asks for the most appropriate next antiarrhythmic.\n\nIn structural heart disease with low EF and VT, class Ic agents (propafenone) are contraindicated; dofetilide is used for AF/flutter, not for VT suppression. The explanation’s claim that dofetilide is effective for VT is not standard or guideline-supported. Sotalol, a class III with beta-blocking properties, is an accepted option for VT suppression in ICD patients with ischemic cardiomyopathy and EF ~25%, provided careful QT and renal monitoring; many guidelines list it as a reasonable next-line antiarrhythmic when amiodarone cannot be used. Thus B is more defensible than C. Mexiletine monotherapy, ranolazine, and propafenone are clearly inferior/unsafe.\n\nMain medical accuracy issue: misrepresentation of dofetilide’s role in VT and overstatement that sotalol is contraindicated purely by low EF.\n\nMinimal fix: Change the key and explanation so that sotalol (B) is the correct answer, and rewrite rationale appropriately; or change option C to a clearly guideline-endorsed VT agent (e.g., catheter ablation rather than another drug).", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-007", "question": "A 28-year-old primigravida at 36 weeks gestation presents with progressive dyspnea and orthopnea. Echocardiography shows peripartum cardiomyopathy with LVEF 30%. After diuresis with furosemide, she remains symptomatic. Which of the following medications should be avoided until after delivery?", "options": ["Digoxin 0.125 mg daily", "Hydralazine 25 mg three times daily", "Isosorbide dinitrate 20 mg three times daily", "Sacubitril/valsartan 24/26 mg twice daily", "Metoprolol succinate 25 mg daily"], "answer": "D", "answer_index": 3, "explanation": "Sacubitril/valsartan contains an ARB (valsartan) which is contraindicated in pregnancy due to fetal renal toxicity and oligohydramnios risk, particularly in the third trimester. Digoxin, hydralazine, isosorbide dinitrate, and metoprolol are all acceptable in pregnancy for heart failure management. While ACE inhibitors and ARBs are absolutely contraindicated, the other medications listed can be used with appropriate monitoring.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 36-week pregnant primigravida with symptomatic peripartum cardiomyopathy (LVEF 30%) despite diuresis; question asks which medication should be avoided until after delivery. In pregnancy, ACE inhibitors, ARBs, and ARNI (sacubitril/valsartan) are contraindicated due to fetotoxicity (renal dysgenesis, oligohydramnios), especially in 2nd/3rd trimesters. Thus sacubitril/valsartan is the uniquely correct “avoid” option.\\nOther options: Digoxin is historically considered safe in pregnancy and used for rate control and HF; hydralazine and isosorbide dinitrate are standard vasodilators for HFrEF in pregnancy when RAAS blockade cannot be used; beta-1–selective beta-blockers like metoprolol are acceptable with monitoring, whereas atenolol is more problematic. None of these are clearly contraindicated in late pregnancy.\\nNo major logical issues: stem gives adequate context; options are comparable HF drugs; only one is clearly contraindicated antenatally. Medical content aligns with current guidance that ARB/ARNI is avoided through pregnancy and can be started postpartum.\\nMinimal fix: Explicitly mention “Which drug is contraindicated during pregnancy for this patient?” to reinforce the focus on pregnancy-related avoidance rather than general HF therapy.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 36-week pregnant primigravida with symptomatic peripartum cardiomyopathy (LVEF 30%) despite diuresis; question asks which medication should be avoided until after delivery. In pregnancy, ACE inhibitors, ARBs, and ARNI (sacubitril/valsartan) are contraindicated due to fetotoxicity (renal dysgenesis, oligohydramnios), especially in 2nd/3rd trimesters. Thus sacubitril/valsartan is the uniquely correct “avoid” option.\nOther options: Digoxin is historically considered safe in pregnancy and used for rate control and HF; hydralazine and isosorbide dinitrate are standard vasodilators for HFrEF in pregnancy when RAAS blockade cannot be used; beta-1–selective beta-blockers like metoprolol are acceptable with monitoring, whereas atenolol is more problematic. None of these are clearly contraindicated in late pregnancy.\nNo major logical issues: stem gives adequate context; options are comparable HF drugs; only one is clearly contraindicated antenatally. Medical content aligns with current guidance that ARB/ARNI is avoided through pregnancy and can be started postpartum.\nMinimal fix: Explicitly mention “Which drug is contraindicated during pregnancy for this patient?” to reinforce the focus on pregnancy-related avoidance rather than general HF therapy.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-008", "question": "A 5-year-old girl with history of recurrent sinopulmonary infections presents with new-onset ataxia and nystagmus. MRI brain shows diffuse cerebellar atrophy. Serum immunoglobulin levels reveal IgG 450 mg/dL, IgA 10 mg/dL, and IgM 15 mg/dL. Flow cytometry shows absent B cells. Which of the following genetic mutations is most likely responsible for this clinical presentation?", "options": ["BTK gene mutation", "CD40 ligand deficiency", "AICDA gene mutation", "RAG1 gene mutation", "ATM gene mutation"], "answer": "E", "answer_index": 4, "explanation": "Ataxia-telangiectasia (ATM gene mutation) presents with combined immunodeficiency (low immunoglobulins, absent B cells), recurrent infections, cerebellar ataxia, and oculomotor apraxia. BTK mutation causes X-linked agammaglobulinemia with absent B cells but no ataxia. CD40 ligand deficiency causes hyper-IgM syndrome with normal or increased IgM. AICDA mutation causes hyper-IgM syndrome type 2. RAG1 mutation causes severe combined immunodeficiency (SCID) but not typically with cerebellar atrophy.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 5-year-old girl with recurrent sinopulmonary infections; new-onset ataxia and nystagmus; MRI with diffuse cerebellar atrophy; hypogammaglobulinemia (low IgG, very low IgA, low IgM); flow cytometry with absent B cells. This constellation (progressive cerebellar neurodegeneration plus immunodeficiency) is classic for ataxia-telangiectasia due to ATM mutation, even though telangiectasias are not mentioned.\\n\\nAlternative choices: BTK (X-linked agammaglobulinemia) also causes absent B cells and low immunoglobulins but does not cause cerebellar atrophy/ataxia and is X-linked (less likely in a girl without mention of skewed X inactivation). CD40L and AICDA defects cause hyper-IgM phenotypes with normal/elevated IgM, not the low IgM given here. RAG1 mutations cause SCID with T- and B-cell defects and severe early infections, not selective cerebellar atrophy/ataxia.\\n\\nMain medical accuracy issues: Minor—ataxia-telangiectasia often shows variable immunoglobulin pattern (classically low IgA, IgG, and elevated/normal IgM), and B-cell numbers may be reduced rather than completely absent, but the pattern still clearly supports ATM.\\n\\nMinimal fix: Clarify “markedly reduced B-cell numbers on flow cytometry” instead of “absent B cells” to better match typical ataxia-telangiectasia findings.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 5-year-old girl with recurrent sinopulmonary infections; new-onset ataxia and nystagmus; MRI with diffuse cerebellar atrophy; hypogammaglobulinemia (low IgG, very low IgA, low IgM); flow cytometry with absent B cells. This constellation (progressive cerebellar neurodegeneration plus immunodeficiency) is classic for ataxia-telangiectasia due to ATM mutation, even though telangiectasias are not mentioned.\n\nAlternative choices: BTK (X-linked agammaglobulinemia) also causes absent B cells and low immunoglobulins but does not cause cerebellar atrophy/ataxia and is X-linked (less likely in a girl without mention of skewed X inactivation). CD40L and AICDA defects cause hyper-IgM phenotypes with normal/elevated IgM, not the low IgM given here. RAG1 mutations cause SCID with T- and B-cell defects and severe early infections, not selective cerebellar atrophy/ataxia.\n\nMain medical accuracy issues: Minor—ataxia-telangiectasia often shows variable immunoglobulin pattern (classically low IgA, IgG, and elevated/normal IgM), and B-cell numbers may be reduced rather than completely absent, but the pattern still clearly supports ATM.\n\nMinimal fix: Clarify “markedly reduced B-cell numbers on flow cytometry” instead of “absent B cells” to better match typical ataxia-telangiectasia findings.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-009", "question": "A 55-year-old man with alcoholic cirrhosis presents with hepatic encephalopathy refractory to lactulose and rifaximin. He has recurrent episodes requiring hospitalization every 2-3 weeks. Transjugular intrahepatic portosystemic shunt (TIPS) is not an option due to severe pulmonary hypertension. Which of the following interventions has the strongest evidence for reducing recurrent hepatic encephalopathy in this patient?", "options": ["Daily polyethylene glycol 3350 17 g", "Empirical vancomycin 125 mg four times daily", "Oral L-ornithine L-aspartate 6 g three times daily", "Sodium benzoate 5 g twice daily", "Branch-chain amino acid supplementation three times daily"], "answer": "A", "answer_index": 0, "explanation": "Polyethylene glycol has been shown in randomized trials to be more effective than lactulose for acute hepatic encephalopathy and may reduce recurrence by more effectively clearing ammonia-producing bacteria from the gut. Vancomycin has similar efficacy to rifaximin but risk of resistance. L-ornithine L-aspartate has modest benefit as adjunct only. Sodium benzoate is second-line. Branch-chain amino acids improve nutrition but not specifically encephalopathy recurrence.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (miskeyed)\\nVerdict on keyed answer: Miskeyed – A is not the best-supported intervention.\\nKey stem clues: 55-year-old with alcoholic cirrhosis, recurrent hepatic encephalopathy despite optimized standard therapy (lactulose + rifaximin), frequent hospitalizations, TIPS contraindicated. Question asks for the intervention with the strongest evidence for reducing *recurrent* HE.\\nEvidence summary: Polyethylene glycol (PEG) 3350 has RCT data mainly for *initial/acute* HE episodes and as cathartic alternative to lactulose; evidence for long-term prevention of recurrence is limited. By contrast, oral branched-chain amino acids (BCAAs) have multiple RCTs and meta-analyses (e.g., Cochrane) showing benefit in improving HE manifestations, particularly in patients intolerant/nonresponsive to standard therapy, with use in chronic/recurrent HE. Sodium benzoate, L-ornithine L-aspartate, and vancomycin each have more limited/adjunct or problematic roles. Thus E is more defensible as having the “strongest evidence” for recurrent HE in this context.\\nMain medical accuracy issue: The explanation overstates PEG’s role in preventing recurrent HE and understates BCAA data.\\nMinimal fix: Change keyed answer and explanation to emphasize branched-chain amino acid supplementation (E) as best-supported adjunct for recurrent HE when standard therapy fails, or reframe the stem to acute HE treatment where PEG could be correct.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (miskeyed)\nVerdict on keyed answer: Miskeyed – A is not the best-supported intervention.\nKey stem clues: 55-year-old with alcoholic cirrhosis, recurrent hepatic encephalopathy despite optimized standard therapy (lactulose + rifaximin), frequent hospitalizations, TIPS contraindicated. Question asks for the intervention with the strongest evidence for reducing *recurrent* HE.\nEvidence summary: Polyethylene glycol (PEG) 3350 has RCT data mainly for *initial/acute* HE episodes and as cathartic alternative to lactulose; evidence for long-term prevention of recurrence is limited. By contrast, oral branched-chain amino acids (BCAAs) have multiple RCTs and meta-analyses (e.g., Cochrane) showing benefit in improving HE manifestations, particularly in patients intolerant/nonresponsive to standard therapy, with use in chronic/recurrent HE. Sodium benzoate, L-ornithine L-aspartate, and vancomycin each have more limited/adjunct or problematic roles. Thus E is more defensible as having the “strongest evidence” for recurrent HE in this context.\nMain medical accuracy issue: The explanation overstates PEG’s role in preventing recurrent HE and understates BCAA data.\nMinimal fix: Change keyed answer and explanation to emphasize branched-chain amino acid supplementation (E) as best-supported adjunct for recurrent HE when standard therapy fails, or reframe the stem to acute HE treatment where PEG could be correct.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-010", "question": "A 34-year-old woman with metastatic HER2-positive breast cancer on trastuzumab, pertuzumab, and docetaxel presents with acute decompensated heart failure. Echocardiography shows global hypokinesis with LVEF 20%, markedly reduced from baseline 55%. Which of the following biomarkers would be most specific for differentiating trastuzumab-induced cardiomyopathy from anthracycline-like toxicity?", "options": ["Elevated serum troponin I with normal NT-proBNP", "Markedly elevated NT-proBNP with normal troponin", "Elevated soluble ST2 with normal galectin-3", "Increased urinary 8-hydroxy-2'-deoxyguanosine", "Elevated growth differentiation factor-15 (GDF-15)"], "answer": "A", "answer_index": 0, "explanation": "Trastuzumab-induced cardiotoxicity typically presents with elevated troponin (indicating myocyte injury) but relatively preserved NT-proBNP (less volume overload/stretch), reflecting its mechanism of reversible HER2 receptor blockade without direct cellular damage. Anthracycline toxicity shows both elevated troponin and markedly elevated NT-proBNP due to irreversible cellular damage. ST2 and galectin-3 are fibrosis markers not specific to this distinction. 8-OHdG is oxidative stress marker. GDF-15 is elevated in various cardiac conditions.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (no answer defensible)\\nVerdict on keyed answer: Misleading/incorrect; no option is clearly correct based on current evidence.\\n\\nKey stem clues: 34-year-old with metastatic HER2+ breast cancer on trastuzumab/pertuzumab/docetaxel, acute decompensated HF, LVEF drop from 55% to 20%. Question asks for a biomarker pattern “most specific for differentiating trastuzumab-induced cardiomyopathy from anthracycline-like toxicity.” No anthracycline exposure mentioned.\\n\\nMain logical issues: The question premise is flawed. Trastuzumab cardiotoxicity is generally type II, often reversible, without classic cumulative-dose structural damage seen with anthracyclines. However, both trastuzumab- and anthracycline-related cardiotoxicity can be associated with troponin elevation and natriuretic peptide elevation; biomarker profiles are not validated as “specific” to distinguish these mechanisms. The keyed explanation (trastuzumab: elevated troponin with preserved NT‑proBNP vs anthracycline: both elevated) is not evidence-based and contradicts typical understanding (trastuzumab less commonly causes troponin rise, NT‑proBNP can be elevated with HF from any cause). Thus option A is not defensibly “most specific,” and none of the other nonspecific biomarkers are either.\\n\\nMain medical accuracy issues: Mischaracterization of trastuzumab vs anthracycline biomarker patterns.\\n\\nMinimal fix: Change the question to ask which biomarkers reflect myocardial injury (troponin) versus wall stress (NT‑proBNP) in chemotherapy cardiotoxicity, or provide evidence-based marker patterns tied to specific agents and rekey accordingly.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (no answer defensible)\nVerdict on keyed answer: Misleading/incorrect; no option is clearly correct based on current evidence.\n\nKey stem clues: 34-year-old with metastatic HER2+ breast cancer on trastuzumab/pertuzumab/docetaxel, acute decompensated HF, LVEF drop from 55% to 20%. Question asks for a biomarker pattern “most specific for differentiating trastuzumab-induced cardiomyopathy from anthracycline-like toxicity.” No anthracycline exposure mentioned.\n\nMain logical issues: The question premise is flawed. Trastuzumab cardiotoxicity is generally type II, often reversible, without classic cumulative-dose structural damage seen with anthracyclines. However, both trastuzumab- and anthracycline-related cardiotoxicity can be associated with troponin elevation and natriuretic peptide elevation; biomarker profiles are not validated as “specific” to distinguish these mechanisms. The keyed explanation (trastuzumab: elevated troponin with preserved NT‑proBNP vs anthracycline: both elevated) is not evidence-based and contradicts typical understanding (trastuzumab less commonly causes troponin rise, NT‑proBNP can be elevated with HF from any cause). Thus option A is not defensibly “most specific,” and none of the other nonspecific biomarkers are either.\n\nMain medical accuracy issues: Mischaracterization of trastuzumab vs anthracycline biomarker patterns.\n\nMinimal fix: Change the question to ask which biomarkers reflect myocardial injury (troponin) versus wall stress (NT‑proBNP) in chemotherapy cardiotoxicity, or provide evidence-based marker patterns tied to specific agents and rekey accordingly.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}]